{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=elranatamab", "query": { "intervention": "elranatamab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 34, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=elranatamab&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-07T08:38:47.509Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06832865", "title": "ELISA in Relapsed/Refractory MM", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed Refractory Multiple Myeloma (RRMM)", "Relapsed Refractory Multiple Myeloma" ], "interventions": [ { "name": "elranatamab", "type": "DRUG" }, { "name": "Isatuximab SC", "type": "DRUG" }, { "name": "Isatuximab SC-OBDS", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-08-14", "completion_date": "2028-12-01", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-06-07T08:38:47.509Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06832865" }, { "nct_id": "NCT06152575", "title": "MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 492, "start_date": "2024-02-08", "completion_date": "2027-12-30", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-06-07T08:38:47.509Z", "location_count": 97, "location_summary": "Mobile, Alabama • Goodyear, Arizona • Beverly Hills, California + 55 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Clovis", "state": "California" }, { "city": "Clovis", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06152575" }, { "nct_id": "NCT05090566", "title": "MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab + Nirogacestat", "type": "DRUG" }, { "name": "Elranatamab + lenalidomide + dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2021-10-27", "completion_date": "2026-03-11", "has_results": true, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-06-07T08:38:47.509Z", "location_count": 22, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Beverly Hills, California + 8 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05090566" }, { "nct_id": "NCT07382739", "title": "A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) \"PRIME-EMD-PMD\"", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Phase 2", "Radiotherapy-Induced Immune Priming", "Elranatamab", "Relapsed Refractory Multiple Myeloma (RRMM)", "Extramedullary Disease in Multiple Myeloma", "Paramedullary Disease", "PMD" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 34, "start_date": "2026-03-31", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-06-07T08:38:47.509Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07382739" }, { "nct_id": "NCT07454382", "title": "A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab-bcmm", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2026-02-27", "completion_date": "2029-08-27", "has_results": false, "last_update_posted_date": "2026-03-06", "last_synced_at": "2026-06-07T08:38:47.509Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07454382" }, { "nct_id": "NCT06947083", "title": "Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloma" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2025-05-27", "completion_date": "2029-04", "has_results": false, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-06-07T08:38:47.509Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06947083" }, { "nct_id": "NCT05932290", "title": "A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" }, { "name": "Standard of care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Weeks", "maximum_age": null, "sex": "ALL", "summary": "18 Weeks and older" }, "enrollment_count": 514, "start_date": "2023-06-01", "completion_date": "2023-07-12", "has_results": true, "last_update_posted_date": "2024-10-29", "last_synced_at": "2026-06-07T08:38:47.509Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05932290" }, { "nct_id": "NCT06592222", "title": "A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" }, { "name": "Standard of care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2024-08-26", "completion_date": "2025-03-03", "has_results": false, "last_update_posted_date": "2025-05-20", "last_synced_at": "2026-06-07T08:38:47.509Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06592222" }, { "nct_id": "NCT06483100", "title": "Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elrantamab", "type": "DRUG" }, { "name": "clonoSEQ", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2024-12-20", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-06-07T08:38:47.509Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06483100" }, { "nct_id": "NCT06121843", "title": "A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "BMS-986393", "type": "DRUG" }, { "name": "Alnuctamab", "type": "DRUG" }, { "name": "Mezigdomide", "type": "DRUG" }, { "name": "Iberdomide", "type": "DRUG" }, { "name": "Elranatamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 147, "start_date": "2024-02-22", "completion_date": "2028-08-01", "has_results": false, "last_update_posted_date": "2026-02-18", "last_synced_at": "2026-06-07T08:38:47.509Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06121843" } ] }